Afficher la notice abrégée

dc.creatorKaltsatou A.en
dc.date.accessioned2023-01-31T08:29:44Z
dc.date.available2023-01-31T08:29:44Z
dc.date.issued2017
dc.identifier10.2174/1381612823666170829164305
dc.identifier.issn13816128
dc.identifier.urihttp://hdl.handle.net/11615/74222
dc.description.abstractBackground: Hypertension is considered a major health problem in patients with chronic kidney disease (CKD) as approximately 80-85% of CKD patients’ suffer from hypertension in the United States. Hypertension is the second leading cause of CKD after diabetes and is strongly related to morbidity and mortality. It has been found that there is a relation among hypertension, glomerular filtration rate (GFR) and creatinine levels. Objective: Since there is a strong relation between hypertension and CKD, and hypertension seems to lead to cardiovascular diseases, which have epidemic proportions in CKD, this review article discusses the etiology of hypertension and the existing optimal therapies that contribute to the hypertension and heart rate management. Results: There are many approaches that contribute to the management of hypertension and heart rate in CKD patients. Lifestyle modifications in combination with drug therapy lead to the better control of hypertension in CKD patients. Conclusion: Hypertension is strongly related to cardiovascular diseases in CKD patients. Since this relation exists and hypertension leads to cardiovascular diseases, the management of hypertension and increased heart rate should be a main therapeutic target in these patients. © 2017 Bentham Science Publishers.en
dc.language.isoenen
dc.sourceCurrent Pharmaceutical Designen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85040371457&doi=10.2174%2f1381612823666170829164305&partnerID=40&md5=cc4d503a7a0a70d7b7d28c0b12e442d4
dc.subjectbeta adrenergic receptor blocking agenten
dc.subjectcalcium antagonisten
dc.subjectdipeptidyl carboxypeptidase inhibitoren
dc.subjectdiuretic agenten
dc.subjectendothelinen
dc.subjecterythropoietinen
dc.subjectnitric oxideen
dc.subjectparathyroid hormoneen
dc.subjectsodiumen
dc.subjectwateren
dc.subjectantihypertensive agenten
dc.subjectadrenergic systemen
dc.subjectantihypertensive therapyen
dc.subjectblood pressureen
dc.subjectblood pressure regulationen
dc.subjectbody weight lossen
dc.subjectcardiovascular diseaseen
dc.subjectchronic kidney failureen
dc.subjectdiet therapyen
dc.subjectdisease associationen
dc.subjectend stage renal diseaseen
dc.subjectexerciseen
dc.subjectheart rateen
dc.subjecthumanen
dc.subjecthypertensionen
dc.subjectlifestyle modificationen
dc.subjectnonhumanen
dc.subjectoxidative stressen
dc.subjectpathophysiologyen
dc.subjectpriority journalen
dc.subjectrenin angiotensin aldosterone systemen
dc.subjectReviewen
dc.subjectsodium restrictionen
dc.subjectblood pressureen
dc.subjectchronic kidney failureen
dc.subjectdrug effecten
dc.subjectheart rateen
dc.subjecthypertensionen
dc.subjectAntihypertensive Agentsen
dc.subjectBlood Pressureen
dc.subjectHeart Rateen
dc.subjectHumansen
dc.subjectHypertensionen
dc.subjectRenal Insufficiency, Chronicen
dc.subjectBentham Science Publishers B.V.en
dc.titleManagement of blood pressure and heart rate in chronic kidney diseaseen
dc.typeotheren


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée